Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Cybin Inc.
< Previous
1
2
3
4
5
6
Next >
Cybin Announces Additional Adelia Milestone Achievement
January 06, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Provides 2021 Year End Summary
December 22, 2021
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in the 11th Annual LifeSci Partners Corporate Access Event and H.C. Wainwright Bioconnect Conference
December 21, 2021
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Awarded Notice of Allowance from U.S. Patent and Trademark Office for CYB004 (Deuterated Psychedelic Tryptamine) for the Treatment of Anxiety Disorders
December 15, 2021
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Confirms Scientific Advice Meeting with UK Medical and Healthcare Products Regulatory Agency for Lead Candidate CYB003 for the Treatment of Major Depressive Disorder and Alcohol Use Disorder
December 08, 2021
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Present at the Stifel GMP 2nd Annual Future of Healthcare Conference on December 8, 2021
December 01, 2021
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals for a Co-Funded Phase 2 Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Distress
November 30, 2021
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6, 2021
November 29, 2021
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Awards Grant for Psychedelic Treatment Clinic at Lenox Hill Hospital to Benefit Underserved Communities
November 23, 2021
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Inc. Reports its Second Quarter Financial Results and Recent Business Highlights
November 15, 2021
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Present at the Jefferies London Healthcare Conference
November 11, 2021
From
Cybin Inc.
Via
Business Wire
Cybin to Announce Second Quarter FY2021 Financial Results and Business Update on November 15, 2021
November 09, 2021
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Positive CYB003 Data Demonstrating Significant Advantages Over Oral Psilocybin for Treatment of Mental Health
November 08, 2021
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Granted DEA Schedule I Manufacturing License
November 04, 2021
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Hosting Research and Development Briefing on November 8, 2021
November 02, 2021
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Launch of EMBARK Psychedelic Facilitator Training Program
October 28, 2021
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces FDA Investigational New Drug Authorization of Cybin’s Sponsored Feasibility Study Using Kernel Flow Technology
October 26, 2021
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Completion of 74 Pre-Clinical Psychedelic Molecule Studies
October 19, 2021
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Files an International Patent Application Covering Psychedelic Delivery Methods
October 12, 2021
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Additional Adelia Milestone Achievements
October 07, 2021
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Appointment of Dr. Amir Inamdar as Chief Medical Officer for European Operations and Dr. Geoff Varty as the Head of Research and Development
October 01, 2021
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Present at Upcoming Cantor and Benzinga Investor Conferences
September 27, 2021
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13th
September 09, 2021
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Additional Adelia Milestone Achievements
August 31, 2021
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Files Two Additional International Patent Applications in Support of the Company’s Research Phase Programs
August 19, 2021
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Files 14th Patent Application Further Strengthening its IP Portfolio and Receives a Favorable Patent Claim Opinion
August 17, 2021
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Election of Theresa Firestone as Director, Results of Shareholders’ Meeting and Adoption of Shareholder Rights Plan
August 16, 2021
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Inc. Announces 2021 First Quarter Financial Results and Business Highlights
August 13, 2021
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
CORRECTING and REPLACING Cybin Announces Additional Adelia Milestone Achievements
August 12, 2021
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Additional Adelia Milestone Achievements
August 12, 2021
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.